Answer Happy

coronaviru £20 million ($24 million) grant from the U.K's National Health Service. The vaccine was made from a weakened version of a common cold virus that causes infections in chimpanzees. It was modified to make it impossible to grow in humans. Proteins from the Covid-19 virus's outer coat were then added. "We hoped the body would recognize and develop an immune response to the COVID-19 protein that will help stop the SARS-CoV-2 virus from entering human cells and therefore prevent infection," the University said. In the trial 1,068 volunteers were recruited. They were assigned by a flip of a coin to either be injected with the coronavirus vaccine or to receive a control - a widely available meningitis vaccine. Volunteers, who lived in a variety of locations around the U.K., were then followed for 6 months. The researchers performed laboratory tests each week to determine if the volunteers had contracted COVID-19 (the disease caused by the coronavirus). The following are the results of the study: Number of people Number of cases of COVID-19 Number of COVID-19 deaths 527 53 (10.0%) 15 (2.8%) People who received the coronavirus vaccine People who received the meningitis vaccine 541 97 (17.9%) 31 (5.7%) "Mortality rate is based on the number of people in the study group. Mortality rate can be calculated frace

meningitis vaccine "Mortality rate is based on the number of people in the study group. Mortality rate can be calculated based on population total or number of cases. Question: What conclusion can be drawn from the collected results of the study? O A lower number of cases and deaths from COVID-19 were observed in the group that received the meningitis vaccine There were a higher number cases and deaths related to COVID-19 in the group that received the coronavirus vaccine. A lower number of cases and deaths from COVID-19 were observed in the group that received the coronavirus vaccine There was no difference in the number of cases and deaths related to COVID-19 between the two groups.